Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)

Anna Angela Di Tucci¹, Roberta Murru¹, Daniele Alberti², Bertrand Rabault², Simona Deplano¹, Emanuele Angelucci¹

¹Unità Operativa Ematologia e Centro Trapianti Midollo Osseo, Ospedale Oncologico ‘Armando Businco’, Cagliari, Italy; ²Novartis Pharma AG, Basel, Switzerland

Case report

The patient (female) was diagnosed in March 2002 at the age of 61 with primary myelofibrosis (PMF) according to the World Health Organization diagnostic criteria (1). The initial symptom was fatigue. The disease was classified as ‘intermediate risk’ according to the prognostic classification of Dupriez et al. (LILLE system) (2), which is associated with a median survival of 26 months. From the time of diagnosis the patient’s hemoglobin was 5–7 g/dL, necessitating packed red blood cell (PRBC) transfusions. The mean cellular volume was 78 fL and blood smear showed red cell poikilocytosis with dacryocytes. The Direct Coombs test was positive without any sign of hemolysis. Bone marrow biopsy showed 20% cellularity with advanced stage of fibrosis, MF-2 according to Thiele et al. (3). From May 2002 to June 2003 the patient required approximately 2–3 PRBC units per month (total of 29 units) to maintain a pretransfusional hemoglobin level of 8.5 g/dL. In June 2003, the patient entered a phase II trial evaluating the efficacy and safety of once-daily oral chelator deferasirox in adults and children with a range of transfusion-dependent anemias. Baseline assessment of this patient (Table 1) showed that bone marrow cellularity had decreased to 10% with no modification in fibrosis score.

With dosing based on liver iron concentration, deferasirox was administered at 20 mg/kg/d for the duration of the 1-yr study. No other hematological therapy was administered during the study period.
After 2 months of deferasirox therapy the patient’s transfusion requirement progressively decreased (10 PRBC units were administered during the initial chelation therapy period) and transfusion therapy was ceased 5 months after study entry due to stable hemoglobin levels of 11.4–12.4 g/dL. At study end, liver iron concentration and serum ferritin levels were significantly reduced (Table 1). Re-evaluation of myelofibrosis by routine hematological evaluation and bone marrow biopsy revealed increased hemoglobin levels (12.5 g/dL), decreased CD34-positive cell counts, a negative Direct Coombs test, a reduction in teardrop cells, and normalization of mean corpuscular volume (90 fL). Bone marrow cellularity had increased to 15% with no modification in fibrosis score. Even if chelation therapy was not directly targeted to PMF a clinical improvement was obtained according to the international working group for myelofibrosis research and treatment response criteria (4). Due to the reduction in transfusions, deferasirox therapy was reduced to a dose of 5 mg/kg/d. Chelation therapy was finally interrupted in January 2005 when the patient’s body iron content was within an acceptable range (serum ferritin 953 µg/L and transferrin saturation 42%). To date (January 2007), the patient remains transfusion free (serum ferritin 499 µg/L and transferrin saturation 34%), with a hemoglobin level of approximately 11 g/dL and normal hematological parameters (platelet count 120 × 10^3/µL).

Discussion

Primary myelofibrosis is an uncommon but severe condition associated with poor prognosis. For the majority of patients, therapy is palliative and many become transfusion dependent. Transfusion requirement often increases during the course of the disease due to collagen deposition in the bone marrow and progressive impairment of erythropoiesis. The patient described here received iron chelation therapy as part of the clinical evaluation of oral deferasirox and experienced not only the anticipated fall in iron levels, but also an unexpected improvement in erythropoiesis. This improvement was so marked that the transfusion requirement decreased progressively and was ultimately deemed unnecessary, an effect that continued after cessation of chelation therapy. Clinical improvement (4) was evident as the patient became transfusion free, leading to a dramatic improvement in quality of life. This has been sustained to date (3 yr after cessation of transfusion requirement and more than 22 months after stopping chelation). Although iron chelation therapy has not been widely evaluated in patients with acquired anemia, reports have shown an improvement in bone marrow function in patients with myelodysplastic syndromes receiving deferoxamine (5) and in a patient with PMF receiving deferiprone (6). A variety of mechanisms are possible in different diseases (7), those postulated include: a limited cytoreductive effect (5), iron redistribution to the hemopoietic tissue (8), ferrokinetic changes (9), suppression of increased apoptosis, and mitochondrial damage secondary to intracellular iron deposition (as it has been demonstrated that iron chelators can pass the erythroblast membrane) (10). Because of the persistent effect after chelation withdrawal, the latter appears to be the most promising mechanism to be investigated. Of course, a stochastic effect cannot be excluded, particularly in PMF in which a ‘bizarre’ behavior has been described (7), but the increasing number of similar reports in the literature support the need for a controlled clinical trial in transfusion-dependent acquired hemopoietic stem cell disorders to investigate the potential benefit of chelation on erythropoiesis.
References

1. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001.

2. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013–8.

3. Thiele J, Kvasnicka HM, Facchetti F, Franco V, Van Der Walt J, Orazi A. European consensus of grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128–32.

4. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497–503.

5. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, Boesen AM, Ellegaard J. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996;94:288–99.

6. Smeets ME, Vreugdenhil G, Holdrinet RS. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol 1996;51:243–4.

7. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272–90.

8. Louache F, Testa U, Pelicci P, Thomopoulos P, Titeux M, Rochant H. Regulation of transferrin receptors in human hematopoietic cell lines. J Biol Chem 1984;259:11576–82.

9. Vreugdenhil G, Smeets M, Feelders RA, Van Eijk HG. Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol 1993;89:57–60.

10. Kontoghiorghes GJ, May A. Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Met 1990;3:183–7.